Shares of Hims & Hers were on fire Monday because the FDA's new leader seems to be a fan of the company's business model.

Canaccord raised the firm’s price target on Hims & Hers to $38 from $28 and keeps a Buy rating on the shares. The stock rallied 70% in ...

Hims & Hers achieved a 44% YoY increase in Q3 2024, surpassing 2 million active users. Find out what positions HIMS as a key ...

On Friday, Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $32.15 which represents a slight increase of $1.81 or 5.97% from the prior close of $30.34. The stock opened at ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

Panaji: Health minister Vishwajit Rane on Monday said that the super-speciality block (SSB) at Goa Medical College at Bambolim will implement the hosp.

Hims & Hers (HIMS) is up 14.0%, or $4.29 to $34.97.Don't Miss our Black Friday Offers:Unlock your investing potential with TipRanks Premium ...

Finding the right treatment for erectile dysfunction (ED) can feel overwhelming with so many options out there! Rugiet, ...

On Wednesday, Hims & Hers Health Inc (HIMS) stock saw a decline, ending the day at $30.34 which represents a decrease of $-0.34 or -1.11% from the prior close of $30.68. The stock opened at $31.49 and ...

Deep-pocketed investors have adopted a bullish approach towards Hims & Hers Health (NYSE:HIMS), and it's something market players shouldn't ignore. Our tracking of public options records at ...